2022 Rare Cancer Think Tank

Presented by TargetCancer Foundation

The Think Tank on Advancing Precision Medicine in Rare Cancers is an interactive, one day meeting that unites clinicians, researchers, industry, patient advocates and patients in a unique format to promote collaboration, information sharing, and idea generation. The diverse perspectives of speakers and attendees will allow for a comprehensive discussion of challenges, goals, opportunities and best practices in addressing the needs of patients facing rare cancers.

View the agenda here.

The Think Tank on Advancing Precision Medicine in Rare Cancers leverages the successful “think tank” model that TargetCancer Foundation has established through over a decade of meetings on other topics, such as gastroesophageal cancers. The Think Tank on Advancing Precision Medicine in Rare Cancers also builds on the progress being made through TargetCancer Foundation’s TCF-001 TRACK study, a nationwide, decentralized, patient-driven clinical trial studying precision medicine in rare cancers, and will feature a mock Molecular Tumor Board meeting featuring members of the TRACK Virtual Molecular Tumor Board.

 Meeting Chairs:
Jennifer Carter, MD, MPH 

Partner, Sandbox Industries; Managing Director, The Blue Venture Fund

John Iafrate, MD, PhD
Deputy Chair of Pathology, Massachusetts General Hospital
Professor of Pathology, Harvard Medical School

Razelle Kurzrock, MD
Professor of Medicine
Founding Director, Michels Rare Cancers Research Laboratories
Froedtert and Medical College of Wisconsin
Principal Investigator, TCF-001 TRACK (Target Rare Cancer Knowledge) Study

 

 

We’re partnering with leading researchers to make a real impact
Learn More